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Abstract  The purpose of this retrospective chart review 
was to determine the correlation between full weight-based 
enoxaparin use and the frequency of anti-Xa concentrations 
within the defined therapeutic range; to ascertain if anti-Xa 
monitoring is being appropriately ordered in relation to the 
timing of enoxaparin dose (after 3 consistent therapeutic 
doses and 3-5 hours post-dose); to establish if the 
evidence-based recommended dose adjustment protocol that 
was studied in the pediatric population was utilized; and if 
this yielded anti-Xa concentrations within the target range 
(0.6 – 1.1 IU/mL) for an adult population. The data may 
suggest a lack of correlation between BMI and whether or 
not the anti-Xa concentration is within the therapeutic range. 
Further prospective studies are needed to confirm this 
finding, and to determine the utility of the available dose 
adjustment nomogram. 
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1. Introduction 
Enoxaparin is a low-molecular-weight heparin (LMWH) 
utilized for deep vein thrombosis (DVT) and pulmonary 
embolism (PE) prophylaxis and treatment, unstable angina, 
and acute myocardial infarction.  Antithrombotic activity is 
achieved by binding to antithrombin III (AT III), which 
inhibits coagulation factors Xa and thrombin (IIa). There is 
more selectivity for inhibition of factor Xa over IIa, in a 
2.7-4:1 ratio. As a result, anti-factor Xa activity can be 
utilized to determine the degree of anticoagulation in patients 
receiving treatment dose enoxaparin.[1] 
The 2012 CHEST guidelines recommend a therapeutic 
dose of 1 mg/kg subcutaneously (SC) every 12 hours or 1.5 
mg/kg SC every 24 hours.  The dose is adjusted for patients 
with a creatinine clearance (CrCl) < 30 mL/min to 1 mg/kg 
every 24 hours. Due to the lack of data in patients with a 
CrCl < 10 mL/min and those on dialysis, enoxaparin is 
generally not recommended in these patients. Therapeutic 
enoxaparin dosing should be based on actual body weight.[2] 
Enoxaparin has more predictable pharmacokinetics than 
unfractionated heparin.[3]  As a result, routine monitoring is 
not recommended. However, in specific patient populations 
anti-Xa monitoring can be utilized to determine the degree of 
anticoagulation.[2]  These patient populations include 
morbid obesity (BMI > 40 kg/m2), renal impairment (CrCl < 
30 mL/min), and pregnancy.[4] Data is lacking in morbidly 
obese patients because many studies exclude this patient 
population.  Many physicians are reluctant to utilize the full 
weight-based dose due to the concern for over 
anticoagulation.[5,6] 
On average, anti-Xa concentrations peak 4 hours 
post-dose, but can occur between 3 to 5 hours post-dose in 
healthy individuals.  The peak provides the best indication 
for enoxaparin anticoagulant activity.[2] Steady state 
concentration is reached on day 2, after two doses of 1.5 
mg/kg every 24 hours or three doses of 1 mg/kg every 12 
hours.[1] As a result, anti-Xa concentrations should be 
drawn 4 hours post-dose on day 2. The therapeutic range 
may differ based on the laboratory analyzing the specimen. 
In general, the therapeutic range is 0.6-1 IU/mL for the 1 
mg/kg every 12 hour dosing or 1-2 IU/mL for the 1.5 mg/kg 
every 24 hour dosing.[2,7] The Indiana University Health 
laboratory where this study was conducted utilized 0.6-1.1 
IU/mL as their therapeutic range. 
 Once an anti-Xa concentration is obtained, there is 
limited available data on how to adjust the dose. Monagle 
and colleagues present a dosing nomogram for pediatric 
patients (see Table 1).[8] However, there are no available 
dose adjustment nomograms in adults. This pediatric 
nomogram has not previously been evaluated in adults. 
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Table 1.  Pediatric Dosing Nomogram8 
Anti-Factor Xa Level IU/mL Hold Next Dose? Dose Change? Repeat Anti-Factor Xa 
< 0.35 No Increase by 25% 4 h after next dose 
0.35 – 0.49 No Increase by 10% 4 h after next dose 
0.5 – 1.0 No No Next day 
1.1 – 1.5 No Decrease by 20% Before next dose 
1.6 – 2.0 3 h Decrease by 30% Before next dose then 4 h after next dose 
> 2.0 Until anti-factor Xa 0.5 IU/mL Decrease by 40% Before next dose, if not <0.5 IU/mL, repeat q12h 
Adapted from Monagle P, Michelson AD, Bovill E, Andrew M. Chest. 2001; 119 (1 Suppl): 344S-370S 
 
Bazinet and colleagues[9] conducted a prospective study 
comparing anti-Xa activity of once-daily vs. twice-daily 
regimens, non-obese patients (BMI 18-30 kg/m2) vs. obese 
patients (BMI > 30 kg/m2), and renal impairment vs. normal 
renal function. Dosing was consistent with the 2012 CHEST 
guideline recommendations. Their data suggested that 
once-daily and twice-daily regimens produce similar anti-Xa 
levels. Anti-Xa concentrations were also similar in obese and 
non-obese patients. Patient weight ranged from 40-159 kg. 
As a result, they concluded that no dosage adjustment was 
necessary for patients weighing up to 159 kg.[9] However, 
data is lacking in patients weighing greater than 159 kg. 
Further research is needed to evaluate anti-Xa concentrations 
following therapeutic weight-based dosing in obese and 
morbidly obese patients, the appropriateness of anti-Xa lab 
draws in clinical practice, and the possible utility of the 
pediatric dose adjustment nomogram in the adult population. 
This retrospective chart review analyzes anti-Xa 
concentrations after therapeutic enoxaparin treatment and 
subsequent dose adjustments. 
2. Materials and Methods 
This was a retrospective cohort study. We conducted a 
Cerner query from May 1, 2011 to April 31, 2012 of patients 
receiving treatment dose enoxaparin and at least one anti-Xa 
concentration during the same admission at an Indiana 
University Health facility (i.e., Methodist, University, North, 
Arnett, and West). The query yielded 100 patients. 
Patients were included if they were at least 18 years of age, 
had an anti-Xa concentration obtained after at least 3 doses 
of enoxaparin on a stable therapeutic-dose regimen, had 
stable renal function, and had an indication for treatment 
dose enoxaparin. Exclusion criteria included prisoners, 
non-enoxaparin anticoagulation that may interfere with 
anti-Xa concentrations, anti-Xa concentration not obtained at 
steady state, unstable renal function necessitating change in 
enoxaparin dose within 3 doses of anti-Xa lab draw, 
prophylactic dose enoxaparin within 3 doses of anti-Xa lab 
draw, treatment dose of enoxaparin not based on actual body 
weight, hemodialysis, peritoneal dialysis, continuous renal 
replacement therapy, estimated creatinine clearance < 10 
mL/min, additional or missed enoxaparin doses within 3 
doses of anti-Xa lab draw, or outpatient treatment. 
2.1. Objectives 
The primary study objectives were to determine the 
correlation between full weight-based enoxaparin use and 
the frequency of anti-Xa concentrations within the defined 
therapeutic target range (0.6 – 1.1 IU/mL), to determine if 
anti-Xa monitoring is being appropriately ordered in relation 
to the timing of the enoxaparin dose, to determine if 
evidence-based recommended dose adjustment protocols are 
utilized, and to determine if there is a difference upon repeat 
anti-Xa concentration between the cohort whose prescribers 
followed the pediatric dosing protocol and those prescribers 
who did not with regard to establishing an anti-Xa 
concentration within the recommended target range. 
Table 2.  Baseline Demographics 
 Median Interquartile Range (IQR) 
Age (years) 58 27.3 
ABW (kg) 97.5 37.5 
IBW (kg) 67 19.0 
BMI (kg/m2) 34 14.8 
LOS (days) 10.5 25.3 
Max SCr (mL/min) 1.09 0.45 
Min CrCl (mL/min) 65.5 49.8 
Min SCr (mL/min) 0.83 0.51 
Max CrCl (mL/min) 111.5 75.0 
2.2. Statistical Analysis  
Twenty-two out of one-hundred patients identified in the 
Cerner query were included.  Due to the non-normal 
distribution of data, descriptive statistics are used to present 
the data, including median and interquartile ranges. As a 
result of the small patient population and lack of power, 
p-values were not able to be utilized. 
2.3. Baseline Demographics 
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Baseline demographics are presented in Table 2. Eleven 
(50%) of the twenty-two patients were male. The indications 
for treatment dose enoxaparin included seventeen patients 
with venous thromboembolism (VTE), two patients with 
atrial fibrillation, three patients with active malignancies, 
and two patients with thrombophilia and previous 
occurrences of VTE. 
Table 3.  Results–Stratified by 1st  Anti-Xa 
Concentration 
Variable 
Anti-Xa in 
Range 
(N=17) 
Anti-Xa Out 
of Range 
(N=5) 
P-Value 
Enoxaparin dose 
(mg) 
100 
(60, 180) 
120 
(80, 140) 0.45 
Enoxaparin dose 
(mg/kg/dose) 
1.01 
(0.83, 1.41) 
1.03 
(0.98, 1.41) 0.62 
# doses prior to 
1st anti-Xa 
4 
(3, 18) 
4 
(3, 25) 0.69 
BMI (kg/m2) 35.5 (18, 68) 
27 
(26, 45) 0.65 
Time (hrs) of 
anti-Xa after last 
dose 
4 
(3, 5) 
4 
(3, 4) 0.51 
Note: Medians presented with minimum, maximum values indicated in 
parentheses. 
3. Results 
The overall median enoxaparin weight-based dose was 
1.025 mg/kg/dose (IQR 0.078). Twenty patients received 
every twelve hour dosing, and two patients received every 
twenty-four hour dosing. The overall median first anti-Xa 
concentration was 0.83 IU/mL (see Table 3). 
Five anti-Xa concentrations were outside of the 
therapeutic range, and seventeen anti-Xa concentrations 
were within the therapeutic range. The BMI ranges for 
patients in the within-range and out-of-range groups were 
18-68 kg/m2 and 26-45 kg/m2 respectively (see Figure 1). 
Only two of the five enoxaparin doses resulting in an 
out-of-range anti-Xa concentration were adjusted (see Table 
4). These two out-of-range anti-Xa levels were 1.27 IU/mL 
and 1.26 IU/mL. According to the dose adjustment 
nomogram presented by Monagle and colleagues[8], it is 
recommended to decrease the enoxaparin dose in both cases 
by 20%. In both cases, the dose was adjusted based on the 
literature. However, a second anti-Xa concentration was 
drawn in only one of these cases. Despite the 20% decrease 
in enoxaparin dose, the anti-Xa concentration increased from 
1.26 to 1.4. Upon further investigation this patient’s serum 
creatinine increased from 0.7 mg/dL to 1.4 mg/dL, 
explaining the increase in the second anti-Xa concentration. 
 
Note: the therapeutic range of the IU Health lab is 0.6 to 1.1 IU/mL, and the level obtained is rounded to the nearest tenth 
Figure 1.  First anti-Xa concentrations classified as “within range” or “out of range” based on each patient’s BMI 
Table 4: Doses Adjusted After First Anti-Xa Concentration 
Dose (mg) Dose (mg/kg) 
Interval 
(hrs) 
First Anti-Xa 
(IU/mL) 
New dose 
(mg) 
New dose 
(mg/kg) 
Interval 
(hrs) 
Second 
Anti-Xa 
(IU/mL) 
Dose change with 
literature? 
120 1.41 q12h 1.27 100 1.18 q12h N/A Yes 
160 1.03 q12h 1.26 130 0.84 q12h 1.4 Yes 
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Table 5.  Exclusions 
Exclusion Criteria Number of Exclusions 
Prisoners 0 
Active pregnancy 0 
Persons <18 years old 0 
Allergy to heparin products 0 
Anti-Xa lab obtained before patient received ≥3 consecutive treatment doses of a stable enoxaparin 
regimen 35 
Anti-Xa lab obtained <3 or >5 hours after enoxaparin dose 31 
Not receiving a treatment dose of enoxaparin equivalent to ABW 30 
Non-enoxaparin anticoagulant use that may interfere with anti-Xa concentration 3 
Patient receiving dialysis or CrCl <10mL/min 6 
No anti-Xa levels drawn 11 
Unstable renal function necessitating a dosage adjustment within 3 doses of anti-Xa level 1 
TOTAL 117 
 
3.1. Exclusions 
In order to determine the appropriateness of anti-Xa lab 
draws in clinical practice, reasons for exclusion were 
analyzed. Seventy-eight patients were excluded for 117 
reasons. Patients could be represented in more than one 
exclusion category. Sixty-six of the 117 reasons for 
exclusion (56%) were inappropriate lab draws. These 
included anti-Xa concentrations obtained outside of the 3-5 
hour post-dose window or prior to steady state. All reasons 
for exclusion are presented in Table 5. 
3.2. Limitations 
The retrospective nature of the study has inherent 
limitations.  We must rely on the accuracy of the charts that 
we reviewed and were limited by the available data.  As a 
result of the lack of control over which dose each patient 
received and when the anti-Xa concentration was drawn, 
many patients were excluded. A small patient population 
remained resulting in an inability to properly analyze the 
primary objectives. The distribution was non-normal and 
therefore Mann-Whitney tests were used to calculate 
medians, IQR’s, and minimum and maximum values. Each 
calculated p-value did not demonstrate statistical 
significance (see Table 3). Only two patients had dose 
adjustments, and only one patient had a repeat anti-Xa level 
drawn after dose adjustment. As a result, we were unable to 
analyze the utility of the dosing nomogram presented by 
Monagle and colleagues in the adult population.[8] 
Lastly, we did not analyze bleeding and thrombotic events 
to determine a correlation between the target anti-Xa range 
(0.6 – 1.1 IU/mL) and adequate anticoagulation. A previous 
study by Spinler and colleagues determined that 
weight-based enoxaparin dosing in obese patients with 
non-ST segment elevation myocardial infarction reduced 
clinical endpoints without a significant risk of major 
hemorrhage.[10] Another study by Barba and colleagues 
found that patients weighing over 100 kg and those weighing 
between 50 – 100 kg on enoxaparin therapy had similar 
incidences of recurrent VTE, fatal pulmonary embolism, and 
major bleeding complications.[11] However, further studies 
are needed to assess target anti-Xa levels and clinical 
outcomes together. 
4. Discussion 
While our study was underpowered to determine statistical 
significance, the data may suggest that there is no correlation 
between BMI and whether or not the anti-Xa concentration is 
within the target range (see Figure 1 & Table 3). These 
results are similar to those of the study conducted by Bazinet 
and colleagues. They determined that there was no 
statistically significant difference between anti-Xa levels 
drawn in obese and non-obese study groups after 
treatment-dose enoxaparin. They included weights up to 159 
kg, and thus determined that no dosage adjustment was 
necessary up to 159 kg.[9] Our study produced similar 
results with patients weighing up to 191 kg. 
Based on the patients excluded from our study, it is 
apparent that anti-Xa concentrations are often drawn 
inappropriately in clinical practice. It is important to 
properly educate health care prescribers and nurses on 
correctly ordering and drawing anti-Xa levels, respectively. 
The patient should be on a consistent regimen for at least 3 
doses, and the level should be drawn between 3 and 5 hours 
post-dose. This laboratory test is expensive, and it is 
important to be able to utilize the result to guide dosage 
adjustment. 
Of the two doses that were adjusted following the first 
anti-Xa concentration, both were consistent with the 
currently available evidence-based recommendations.  
Literature recommendations, however, are only available for 
the pediatric population. As a result, it is important to 
determine if these recommendations can be extrapolated to 
the adult population. Our study did not include enough 
patients with dose adjustments to analyze the use of this 
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pediatric nomogram in adults. We were also unable to draw 
any conclusions from the data about repeat anti-Xa levels 
after dose adjustment because only one patient had a second 
level drawn. 
5. Conclusion 
The data from this retrospective chart review may suggest 
that a correlation is lacking between BMI and whether or not 
the anti-Xa concentration is within the therapeutic range. 
However, higher powered studies would be needed to verify 
this result. Further prospective studies would be beneficial to 
determine the utility of the currently available pediatric dose 
adjustment nomogram in adults. 
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